Clinical Roundup DREAMM-2 demonstrates meaningful ORR with belantamab mafodotin in multiple myeloma January 03, 2020Vol.46 No.01
Clinical RoundupFree PD-1 inhibitor treatment prior to stem cell transplant is safe, effective in classic Hodgkin lymphoma December 13, 2019Vol.45 No.46
Clinical RoundupFree BMS’s liso-cel met primary, secondary endpoints in TRANSCEND NHL 001 December 13, 2019Vol.45 No.46
Clinical RoundupFree Phase II KarMMa study of ide-cel in relapsed, refractory multiple myeloma meets ORR primary endpoint December 13, 2019Vol.45 No.46
Clinical RoundupFree Seattle Genetics announces positive OS, PFS, ORR for tucatinib in HER2+ breast cancer December 13, 2019Vol.45 No.46
Clinical RoundupFree ctDNA may help predict recurrence in patient with early triple-negative breast cancer December 13, 2019Vol.45 No.46
Clinical RoundupFree Extended follow-up phase III data underscore sustained efficacy and safety of Imbruvica in CLL December 13, 2019Vol.45 No.46
Clinical RoundupFree Phase III TOURMALINE-AL1 trial of Ninlaro in patients with amyloidosis didn’t meet one of two primary endpoints December 13, 2019Vol.45 No.46
Clinical RoundupFree Phase III SOPHIA study shows margetuximab didn’t reach significance for OS in HER2+ metastatic breast cancer December 13, 2019Vol.45 No.46
Clinical RoundupFree Keytruda improved OS in frontline metastatic NSCLC regardless of KRAS status December 13, 2019Vol.45 No.46
